UNSPSC 51123204: Butoprozine

This classification denotes an antiarrhythmic agent with the molecular formula C28H38N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9XWF3530OG chemically known as methanone, (4-(3-(dibutylamino)-propoxy)phenyl)(2-ethyl-3-indolizinyl)-, but more commonly known as butoprozine, which bears US NIH Compound Identifier 71959. European Medicines Agency schedules Butoprozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06033MIG. The term BUTOPROZINE is an International Non-Proprietary Name or INN.

UNSPSC 51123204 Butoprozine, a Commodity code, encompasses advanced life support and emergency medications purchased by municipal fire-rescue services, state health agencies, and cooperative purchasing alliances for distribution through established pharmaceutical wholesaler networks. State and local governments procure this medication—along with complementary emergency pharmaceuticals like epinephrine, adenosine, and diltiazem—for pre-hospital and acute-care protocols. Issuing bodies span municipal fire departments (the City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The solicitations reflect a mix of direct municipal procurement and broader multi-jurisdictional frameworks that aggregate demand across state and local participants.

Recent activity appears concentrated in the South and Upper Midwest. The City of Tampa issued an IFB in April 2026 for Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026, estimated contract value $40,000) requiring 1,020 units of Diltiazem 25mg vials and other emergency drugs with nine-month minimum shelf life and firm pricing including freight to Tampa. Texas HHS issued a Request for Information in April 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling interest in alternative supply-chain structures. MMCAP, administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) to establish multi-award generic pharmaceutical contracts across participating state and local facilities in Minnesota and Oregon, effective July 1, 2026, with pricing weighted at 75 percent of evaluation and participation limited to vendors maintaining relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). Bidders must comply with cGMP, DSCSA, FDA requirements, OSHA Safety Data Sheets, and WCAG 2.2 accessibility standards, with insurance requirements up to $5,000,000 general liability per occurrence in the cooperative context.